RxDoctor Payments Data

Jae Graham, PA

Physician Assistant · Houston, TXNPI 1417093253

Payments from drug & device makers

$1,700in general payments, 2019–2025

Across 84 payments — averaging $20.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$396
  • GSK$218
  • Abbott$213
  • Novo Nordisk$198
  • AbbVie$142
  • Amarin Pharma, Inc.$79
  • plus $454 from 11 others

What the payments were for

  • Food & beverage$1,700100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,700 in reported general payments places this provider in the 70th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$3,505
Medicare patients
23
Services billed
63

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin32$37,576
RybelsusSemaglutide16$31,630
OzempicSemaglutide21$26,208
JanuviaSitagliptin Phosphate22$25,919
FarxigaDapagliflozin Propanediol19$21,498
EliquisApixaban17$20,731
MounjaroTirzepatide13$16,179
LinzessLinaclotide13$11,654
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$10,489
Tresiba Flextouch U-200Insulin Degludec11$10,183
Tresiba Flextouch U-100Insulin Degludec20$9,425
Breo ElliptaFluticasone/Vilanterol15$5,874
Sucralfate16$3,894
Rosuvastatin Calcium211$3,705
Albuterol Sulfate HfaAlbuterol Sulfate104$3,270

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$198$57,83737 claims
Boehringer IngelheimJardiance$73$37,57632 claims
MerckJanuvia$19$25,91922 claims
AstraZenecaFarxiga$61$21,49819 claims
PfizerEliquis$60$20,73117 claims
GSKTrelegy Ellipta, Breo Ellipta$218$16,36231 claims
Lilly USA, LLCMounjaro$396$16,17913 claims
AbbVieLinzess, Synthroid$142$12,33632 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →